Clinical efficacy of the combination treatment of psoriasis vulgaris with crisaborole ointment in comparison with calcipotriene ointment

Summary: Abstract Body: The present study was designed to observe the clinical efficacy and evaluate the safety of the combination of Crisaborole ointment and Captopanol ointment in the treatment of psoriasis vulgaris by self-monitoring. A total of 30 subjects were included in the study, including 16 males and 14 females with a mean age of 42.00±8.94 years. The left upper or lower extremity was designated as the treatment group and the right side as the control group. The control side (control group) was treated with topical Crisaborole ointment both in the morning and in the evening, and the treatment side (treatment group) was treated with topical calcipotriol ointment in the morning and topical Crisaborole ointment in the evening for a total of 4 weeks. Clinical symptoms were scored and adverse reactions were recorded at weeks 1, 2, and 4 of treatment, respectively. The results showed that after 1 week of treatment, the clinical symptom scores of both the control and treatment groups were significantly decreased compared with the pretreatment period (P<0.05), but the difference between the two groups was not statistically significant (P>0.05); the PASI scores of both groups were significantly decreased compared with the pretreatment period after 2 weeks and 4 weeks of treatment (P<0. 05), and the overall therapeutic efficacy of the treatment group (with an effective cure rate of 38.46%) was better than that of the control group (28.91%) (P<0.05); the overall incidence of adverse reactions in the treatment group was lower than that of the control group (P<0.05). The results of the study showed that the efficacy of Crisaborole Ointment combined with Captopanol Ointment in the treatment of psoriasis vulgaris was remarkable, which could effectively alleviate the clinical symptoms and improve the skin condition with good therapeutic effect and safety, and provided a new and effective choice for the treatment of psoriasis. Rongzhu Yu¹, Liwei Feng¹, Xiaolin Bu² 1. School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, China. 2. Dermatology, Shanghai Pudong New Area Gongli Hospital, Shanghai, China. Clinical Research: Epidemiology and Observational Research